title: Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication.
abstract: OBJECTIVE
  The aim of this prospective study was to compare the efficacy of the first-line lansoprazole-based sequential therapy and concomitant therapy (lansoprazole, amoxicillin, clarithromycin and metronidazole) for Helicobacter pylori (H. pylori) eradication.
  
  
  METHODS
  A total of 169 patients with H. pylori infection were randomly assigned to either the sequential therapy group (n = 85) or the concomitant therapy group (n = 84). A follow-up endoscopy or urea breath test was examined at least 12 weeks after eradication.
  
  
  RESULTS
  Comparable H. pylori eradication rate was observed in both the sequential therapy and concomitant therapy groups by either intention-to-treat analysis [sequential 80.0% (68/85) vs concomitant 88.1% (74/84); P = 0.27] or per protocol analysis [sequential, 85.3% (64/75) vs concomitant, 94.6% (70/74); P = 0.60]. Adverse effects were reported and good compliance was observed in both groups (P = 0.72). Although dual antibiotics resistance affected the therapeutic efficacy of sequential therapy (P = 0.03), not concomitant therapy (P = 0.74), it was not an independent factor for predicting the treatment outcome.
  
  
  CONCLUSIONS
  First-line lansoprazole-based sequential and concomitant therapy were well-tolerated and comparable in terms of their H. pylori eradication rate.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Ten Chan Hospital, Chung-Li, Taoyuan, China.
authors.forename: Yao-Kang
authors.initials: YK
authors.lastname: Huang
authors.forename: Meng-Chieh
authors.initials: MC
authors.lastname: Wu
authors.forename: Sophie Sw
authors.initials: SS
authors.lastname: Wang
authors.forename: Chao-Hung
authors.initials: CH
authors.lastname: Kuo
authors.forename: Yi-Chern
authors.initials: YC
authors.lastname: Lee
authors.forename: Ling-Li
authors.initials: LL
authors.lastname: Chang
authors.forename: Tsung-Hsi
authors.initials: TH
authors.lastname: Wang
authors.forename: Yen-Hsu
authors.initials: YH
authors.lastname: Chen
authors.forename: Wen-Ming
authors.initials: WM
authors.lastname: Wang
authors.forename: Deng-Chyang
authors.initials: DC
authors.lastname: Wu
authors.forename: Fu-Chen
authors.initials: FC
authors.lastname: Kuo
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage*; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D000890:Anti-Infective Agents / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D017291:Clarithromycin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005756:Gastritis / Q000188:drug therapy / Q000382:microbiology / Q000473:pathology; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D064747:Lansoprazole; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage*; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin